The Receptor Tyrosine Kinase AXL Promotes Migration and Invasion in Colorectal Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Jul 21

PMID 28727830

Citations 24

Authors

Diana J Uribe

Edward K Mandell

Adam Watson

Jesse D Martinez

Jonathan A Leighton

Sourav Ghosh

Carla V Rothlin

Affiliations

Soon will be listed here.

Abstract

The receptor tyrosine kinases (RTKs) TYRO3, AXL and MERTK (TAM) have well-described oncogenic functions in a number of cancers. Notwithstanding, TAM RTKs are also potent and indispensable inhibitors of inflammation. The combined deletion of Axl and Mertk in mice enhances chronic inflammation and autoimmunity, including increased inflammation in the gut and colitis-associated cancer. On the other hand, deletion of Tyro3 increases the risk of allergic responses. Therefore, the indiscriminate inhibition of these TAM RTKs could result in undesirable immunological diseases. Here we show that AXL, but not MERTK or TYRO3 expression is enhanced in late stage colorectal cancer (CRC) and AXL expression associates with a cell migration gene signature. Silencing AXL or the inhibition of AXL kinase activity significantly inhibits tumor cell migration and invasion. These results indicate that the selective inhibition of AXL alone might confer sufficient therapeutic benefit in CRC, while preserving at least some of the beneficial, anti-inflammatory effects of MERTK and TYRO3 RTKs.

Citing Articles

Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.

Kim D, Synn C, Lee W, Jo H, Lee C, Lee S Mol Cancer Ther. 2024; 24(3):354-369.

PMID: 39632711 PMC: 11876964. DOI: 10.1158/1535-7163.MCT-24-0501.

A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma.

Dayyani F, Balangue J, Valerin J, Keating M, Zell J, Taylor T Clin Colorectal Cancer. 2023; 23(1):67-72.

PMID: 38103947 PMC: 11265208. DOI: 10.1016/j.clcc.2023.11.001.

Receptor tyrosine kinases: biological functions and anticancer targeted therapy.

Zhang N, Li Y MedComm (2020). 2023; 4(6):e446.

PMID: 38077251 PMC: 10701465. DOI: 10.1002/mco2.446.

Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis.

Vasilogianni A, Al-Majdoub Z, Achour B, Peters S, Rostami-Hodjegan A, Barber J Front Oncol. 2023; 13:1010563.

PMID: 36890818 PMC: 9986493. DOI: 10.3389/fonc.2023.1010563.

MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.

Yan D, Huelse J, Kireev D, Tan Z, Chen L, Goyal S J Clin Invest. 2022; 132(15).

PMID: 35708914 PMC: 9337831. DOI: 10.1172/JCI150517.

References

Lemke G, Rothlin C . Immunobiology of the TAM receptors. Nat Rev Immunol. 2008; 8(5):327-36. PMC: 2856445. DOI: 10.1038/nri2303. View

Lemmon M, Schlessinger J . Cell signaling by receptor tyrosine kinases. Cell. 2010; 141(7):1117-34. PMC: 2914105. DOI: 10.1016/j.cell.2010.06.011. View

Maurer C, Friess H, Kretschmann B, Wildi S, Muller C, Graber H . Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. Int J Cancer. 1998; 79(1):76-81. DOI: 10.1002/(sici)1097-0215(19980220)79:1<76::aid-ijc15>3.0.co;2-f. View

Sawabu T, Seno H, Kawashima T, Fukuda A, Uenoyama Y, Kawada M . Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Mol Carcinog. 2006; 46(2):155-64. DOI: 10.1002/mc.20211. View

Wu C, Li A, Chi C, Lai C, Huang C, Lo S . Clinical significance of AXL kinase family in gastric cancer. Anticancer Res. 2002; 22(2B):1071-8. View

Zagorska A, Traves P, Lew E, Dransfield I, Lemke G . Diversification of TAM receptor tyrosine kinase function. Nat Immunol. 2014; 15(10):920-8. PMC: 4169336. DOI: 10.1038/ni.2986. View

Carrera Silva E, Chan P, Joannas L, Errasti A, Gagliani N, Bosurgi L . T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response. Immunity. 2013; 39(1):160-70. PMC: 4017237. DOI: 10.1016/j.immuni.2013.06.010. View

Zhang S, McCrudden C, Yuen H, Leung K, Hong W, Kwok H . Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer. Oncol Lett. 2016; 11(2):1223-1229. PMC: 4734239. DOI: 10.3892/ol.2015.3999. View

Akitake-Kawano R, Seno H, Nakatsuji M, Kimura Y, Nakanishi Y, Yoshioka T . Inhibitory role of Gas6 in intestinal tumorigenesis. Carcinogenesis. 2013; 34(7):1567-74. DOI: 10.1093/carcin/bgt069. View

10.

Sheridan C . First Axl inhibitor enters clinical trials. Nat Biotechnol. 2013; 31(9):775-6. DOI: 10.1038/nbt0913-775a. View

11.

Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F . Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1814-23. PMC: 5024539. DOI: 10.1056/NEJMoa1510016. View

12.

Kariolis M, Miao Y, Jones 2nd D, Kapur S, Mathews I, Giaccia A . An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis. Nat Chem Biol. 2014; 10(11):977-83. PMC: 4372605. DOI: 10.1038/nchembio.1636. View

13.

Li B, Dewey C . RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12:323. PMC: 3163565. DOI: 10.1186/1471-2105-12-323. View

14.

Blume-Jensen P, Hunter T . Oncogenic kinase signalling. Nature. 2001; 411(6835):355-65. DOI: 10.1038/35077225. View

15.

Ochiumi T, Kitadai Y, Tanaka S, Akagi M, Yoshihara M, Chayama K . Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer. Int J Oncol. 2006; 29(1):105-16. View

16.

von Massenhausen A, Bragelmann J, Billig H, Thewes B, Queisser A, Vogel W . Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. Int J Mol Sci. 2016; 18(1). PMC: 5297642. DOI: 10.3390/ijms18010007. View

17.

Linger R, Keating A, Earp H, Graham D . Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets. 2010; 14(10):1073-90. PMC: 3342018. DOI: 10.1517/14728222.2010.515980. View

18.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

19.

Linger R, Cohen R, Cummings C, Sather S, Migdall-Wilson J, Middleton D . Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene. 2012; 32(29):3420-31. PMC: 3502700. DOI: 10.1038/onc.2012.355. View

20.

Rothlin C, Lemke G . TAM receptor signaling and autoimmune disease. Curr Opin Immunol. 2010; 22(6):740-6. PMC: 2997887. DOI: 10.1016/j.coi.2010.10.001. View